167 related articles for article (PubMed ID: 26762806)
1. Statin Use and Breast Cancer Risk in the Nurses' Health Study.
Borgquist S; Tamimi RM; Chen WY; Garber JE; Eliassen AH; Ahern TP
Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):201-6. PubMed ID: 26762806
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for hormone receptor-defined breast cancer in postmenopausal women.
Rosenberg LU; Einarsdóttir K; Friman EI; Wedrén S; Dickman PW; Hall P; Magnusson C
Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2482-8. PubMed ID: 17164374
[TBL] [Abstract][Full Text] [Related]
3. Long-term statin use and risk of ductal and lobular breast cancer among women 55 to 74 years of age.
McDougall JA; Malone KE; Daling JR; Cushing-Haugen KL; Porter PL; Li CI
Cancer Epidemiol Biomarkers Prev; 2013 Sep; 22(9):1529-37. PubMed ID: 23833125
[TBL] [Abstract][Full Text] [Related]
4. Progestagens use before menopause and breast cancer risk according to histology and hormone receptors.
Fabre A; Fournier A; Mesrine S; Gompel A; Desreux J; Berrino F; Boutron-Ruault MC; Romieu I; Clavel-Chapelon F
Cancer Epidemiol Biomarkers Prev; 2008 Oct; 17(10):2723-8. PubMed ID: 18843015
[TBL] [Abstract][Full Text] [Related]
5. Molecular Subtypes and Prognostic Factors among Premenopausal and Postmenopausal Thai Women with Invasive Breast Cancer: 15 Years Follow-up Data.
Tubtimhin S; Promthet S; Suwanrungruang K; Supaattagorn P
Asian Pac J Cancer Prev; 2018 Nov; 19(11):3167-3174. PubMed ID: 30486605
[TBL] [Abstract][Full Text] [Related]
6. Reproductive risk factor associations with lobular and ductal carcinoma in the Carolina Breast Cancer Study.
Williams LA; Nichols HB; Hoadley KA; Tse CK; Geradts J; Bell ME; Perou CM; Love MI; Olshan AF; Troester MA
Cancer Causes Control; 2018 Jan; 29(1):25-32. PubMed ID: 29124544
[TBL] [Abstract][Full Text] [Related]
7. Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya.
Sayed S; Moloo Z; Wasike R; Bird P; Oigara R; Govender D; Kibera J; Carrara H; Saleh M
Breast; 2014 Oct; 23(5):591-6. PubMed ID: 25012047
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer as heterogeneous disease: contributing factors and carcinogenesis mechanisms.
Kravchenko J; Akushevich I; Seewaldt VL; Abernethy AP; Lyerly HK
Breast Cancer Res Treat; 2011 Jul; 128(2):483-93. PubMed ID: 21225455
[TBL] [Abstract][Full Text] [Related]
9. Hormone receptor-negative breast cancer: undertreatment of patients over 80.
Weiss A; Noorbakhsh A; Tokin C; Chang D; Blair SL
Ann Surg Oncol; 2013 Oct; 20(10):3274-8. PubMed ID: 23838924
[TBL] [Abstract][Full Text] [Related]
10. Unopposed estrogen therapy and the risk of invasive breast cancer.
Chen WY; Manson JE; Hankinson SE; Rosner B; Holmes MD; Willett WC; Colditz GA
Arch Intern Med; 2006 May; 166(9):1027-32. PubMed ID: 16682578
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer biology and ethnic disparities in breast cancer mortality in new zealand: a cohort study.
Seneviratne S; Lawrenson R; Scott N; Kim B; Shirley R; Campbell I
PLoS One; 2015; 10(4):e0123523. PubMed ID: 25849101
[TBL] [Abstract][Full Text] [Related]
12. Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users.
Kumar AS; Benz CC; Shim V; Minami CA; Moore DH; Esserman LJ
Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1028-33. PubMed ID: 18463402
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for specific histopathological types of postmenopausal breast cancer in the NIH-AARP Diet and Health Study.
Nyante SJ; Dallal CM; Gierach GL; Park Y; Hollenbeck AR; Brinton LA
Am J Epidemiol; 2013 Aug; 178(3):359-71. PubMed ID: 23899816
[TBL] [Abstract][Full Text] [Related]
14. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer.
Li CI; Malone KE; Porter PL; Weiss NS; Tang MT; Cushing-Haugen KL; Daling JR
JAMA; 2003 Jun; 289(24):3254-63. PubMed ID: 12824206
[TBL] [Abstract][Full Text] [Related]
15. A study of high-nuclear-grade breast cancer in Thailand: subclassification and correlation with prognostic factors and immunohistochemical study.
Chaiwun B; Nakrungsee S; Sukhamwang N; Srisukho S
Breast Cancer; 2010; 17(1):35-41. PubMed ID: 19789946
[TBL] [Abstract][Full Text] [Related]
16. COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin.
Holmes MD; Chen WY; Schnitt SJ; Collins L; Colditz GA; Hankinson SE; Tamimi RM
Breast Cancer Res Treat; 2011 Nov; 130(2):657-62. PubMed ID: 21728052
[TBL] [Abstract][Full Text] [Related]
17. Triple-negative breast cancers: unique clinical presentations and outcomes.
Billar JA; Dueck AC; Stucky CC; Gray RJ; Wasif N; Northfelt DW; McCullough AE; Pockaj BA
Ann Surg Oncol; 2010 Oct; 17 Suppl 3():384-90. PubMed ID: 20853062
[TBL] [Abstract][Full Text] [Related]
18. Is there a correlation between breast cancer molecular subtype using receptors as surrogates and mammographic appearance?
Killelea BK; Chagpar AB; Bishop J; Horowitz NR; Christy C; Tsangaris T; Raghu M; Lannin DR
Ann Surg Oncol; 2013 Oct; 20(10):3247-53. PubMed ID: 23975299
[TBL] [Abstract][Full Text] [Related]
19. Migraine in postmenopausal women and the risk of invasive breast cancer.
Mathes RW; Malone KE; Daling JR; Davis S; Lucas SM; Porter PL; Li CI
Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3116-22. PubMed ID: 18990752
[TBL] [Abstract][Full Text] [Related]
20. RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.
Habashy HO; Powe DG; Glaab E; Ball G; Spiteri I; Krasnogor N; Garibaldi JM; Rakha EA; Green AR; Caldas C; Ellis IO
Breast Cancer Res Treat; 2011 Jul; 128(2):315-26. PubMed ID: 20697807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
